Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations

Journal of Virological Methods

Volumn 73, Issue 1, 1998, Pages 77-82

  Schmit, Jean Claude ^a   Ruiz, Lidia ^b   Stuyver, Lieven ^b   Van Laethem, Kristel ^a   Vanderlinden, Ilse ^a   Puig, Theresa ^b   Rossau, Rudi ^b   Desmyter, Jan ^a   De Clercq, Erik ^a   Clotet, Bonaventura ^b   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

DNA sequencing; HIV drug resistance; LiPA HIV 1 RT; Selective PCR

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; LAMIVUDINE; ZALCITABINE; ZIDOVUDINE;

ACCURACY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA SEQUENCE; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TECHNIQUE; VIRUS MUTATION;

ANTI-HIV AGENTS; CODON; DIDANOSINE; DNA PROBES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; ZALCITABINE; ZIDOVUDINE;

EID: 0031713505     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(98)00043-3     Document Type: Article

References (18)

1. Caesar Coordinating Committee Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 349:1997;1413-1421.
2. Felsenstein, J., 1989. PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics 164-165.
3. 3. In Program and Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC. Abstract LB7.
4. Japour A.J., Mayers D.L., Johnson V.A.et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1993;1095-1101.
5. Kaye S., Loveday C., Tedder R.S. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J. Med. Virol. 37:1992;241-246.
6. Kellam P., Larder B.A. Recombinant virus assay: a rapid, phenotypic assay for assessement of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:1994;23-30.
7. Larder, B.A., Boucher, C.A.B., 1993. PCR detection of human immunodeficiency virus drug resistance mutations. In: Persing, D.H. (Ed.), Diagnostic Molecular Microbiology, Principles and Applications, American Society for Microbiology, Washington, pp. 527-533.
8. Larder B.A., Kemp S.D. Multiple mutations in the HIV-1 reverse transcriptase confer high-level resistance to zidovudine (ZDV). Science. 46:1989;1155-1158.
9. Larder B.A., Kellam P., Kemp S.D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 5:1991;137-144.
10. Larder B.A., Kohli A., Bloor S.et al. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus dideoxycytidine combination therapy. J. Virol. 70:1996;5922-5929.
11. Ruiz L., Romeu J., Martinez-Picado J.et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. AIDS. 10:1996;F61-66.
12. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 4:1996;95-107.
13. Schmit J.C., Cogniaux J., Hermans P.et al. Multiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J. Infect. Dis. 174:1996;962-968.
14. Schmit, J.C., Martinez-Picado, J., Ruiz, L. et al., 1998. Evolution of HIV drug resistance in ZDV/ddC- and ZDV/ddI experienced patients receiving 3TC-containing combination therapy, Antiviral Therapy (in press).
15. Stuyver L., Wyseur A., Rombout A.et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:1997;284-291.
16. Tan C.K., Zhang K.M., So A.G. Functional characterization of RNA-dependant DNA polymerase and Rnase H activities of a recombinant HIV reverse transcriptase. Biochemistry. 30:1991;2651-2655.
17. Vandamme A.M., Van Dooren S., Kok W.et al. Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J. Virol. Meth. 52:1995;121-132.
18. Vandamme, A.M., Witvrouw, M., Pannecouque, C. et. al., 1998. Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In Schinazi, R. (Ed.), Methods in Molecular Biology: Antiviral Testing (in press).